Indications and clinical use:

WAINUA (eplontersen injection) is indicated for the treatment of polyneuropathy associated with stage 1 or stage 2 hereditary transthyretin-mediated amyloidosis in adults.

Relevant warnings and precautions:

• Reduced serum vitamin A levels and recommended supplementation
• Driving and operating machinery
• Potential risk of ocular symptoms
• Use in pregnant or breastfeeding women
• Risks related to reproductive health, including teratogenic risk

For more information:

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which has not been discussed in this piece.

The Product Monograph is also available by calling 1-877-404-8277 or emailing ask-medical@astrazeneca.ca.

Reference: WAINUA® Product Monograph. AstraZeneca Canada Inc. August 26, 2025.